BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
See today's BioWorld
Home
» JAK be not quick: CRL hits Lilly/Incyte on baricitinib, wants more data on dose
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
JAK be not quick: CRL hits Lilly/Incyte on baricitinib, wants more data on dose
April 17, 2017
By
Randy Osborne
No Comments
Bad news came on Good Friday for Incyte Corp. and Eli Lilly and Co. in the form of a complete response letter (CRL) from the FDA related to once-daily, oral baricitinib for moderate to severe rheumatoid arthritis (RA).
BioWorld